Filing Details
CRESCENT BIOPHARMA, INC. (NASDAQ:CBIO) filed its quarterly report (Form 10-Q) with the Securities and Exchange Commission on July 30, 2026.
The Healthcare company reported Q0 revenue of .
Filing Details CRESCENT BIOPHARMA, INC. (NASDAQ:CBIO) filed its quarterly report (Form 10-Q) with the Securities and Exchange Commission on July 30, 2026. The Healthcare company…
CRESCENT BIOPHARMA, INC. (NASDAQ:CBIO) filed its quarterly report (Form 10-Q) with the Securities and Exchange Commission on July 30, 2026.
The Healthcare company reported Q0 revenue of .
CRESCENT BIOPHARMA, INC.'s stock currently trades at $15.02 with a market capitalization of $213.7M.
The 10-Q provides CRESCENT BIOPHARMA, INC.'s quarterly financial update, including unaudited financial statements and management commentary on recent performance. While less detailed than the annual 10-K, the 10-Q often contains timely information about emerging trends, updated risk factors, and changes in business conditions since the last filing.
All SEC filings for CRESCENT BIOPHARMA, INC. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View CBIO Stock Page
Browse all filings on our CBIO SEC filings page.
Public companies like CRESCENT BIOPHARMA, INC. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.
Current market data
NASDAQ · CBIO
$16.60
Down: -$1.15 · -6.48%
Live quote updated
Keep reading